Abstract
Immune checkpoint inhibitors (ICIs) are a cornerstone in oncological treatment, and are known to induce gastrointestinal side effects, most commonly colitis. However less commonly, immune checkpoint inhibitors can cause gastritis in patients. We present a 71-year-old male with a history of metastatic castrate-resistant prostatic carcinoma on pembrolizumab therapy who presented to the emergency department with melaena, haematemesis and anaemia. Gastroscopy revealed blood in stomach, sloughy and erythematous gastric mucosa, multiple antral erosions and ulcerations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
